CN107397764A - Pharmaceutical composition for adjuvant treatment of cancer - Google Patents

Abstract

The invention provides a pharmaceutical composition for adjuvant therapy of cancer, which is antrodia camphorata extract, ganoderma lucidum extract or a combination thereof with a specific dose of 50-250 mu g/mL. Unlike available technology, which uses anticancer medicine or radioactive matter to kill cancer cell, the present invention uses Antrodia camphorata wine extract, glossy ganoderma wine extract or Antrodia camphorata wine extract as novel medicine composition to reach the medical functions of killing lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231 and colorectal cancer cell HT 29. In addition, compared with the existing anticancer drugs or radioactive substances which have side effects of causing nausea, vomiting, inappetence and the like of patients, the antrodia camphorata wine extract, the ganoderma lucidum wine extract or the antrodia camphorata wine extract not only can achieve the effect of killing cancer cells, but also has the effects of clearing away heat and toxic materials, enhancing the immunity and increasing the appetite.

Description

Pharmaceutical composition for adjuvant treatment of cancer

technical field

The invention relates to the technical field of medical compositions, in particular to a medicinal composition extracted from Ganoderma lucidum and/or Antrodia camphorata for auxiliary treatment of cancer.

Background technique

According to the Health Promotion Administration, Ministry of Health and Welfare, the number of cancer patients in Taiwan increased by 2,499 in 2013 compared to 2012. It is worth noting that the total number of patients suffering from colorectal cancer, lung cancer, liver cancer, or breast cancer accounts for 50% of all cancer cases.

Currently, surgery is the main treatment for lung cancer. However, because lung cancer is difficult to diagnose early, 70% of lung cancer patients are usually in a locally advanced state when they are diagnosed. Therefore, after surgical resection of the lesion, the attending doctor usually gives radiation therapy to locally advanced cancer (Locally Advanced Cancer). However, radiation therapy for lung cancer has acute side effects, such as: fatigue, lethargy, loss of appetite, peeling phenomenon, radiation pneumonitis, etc. Therefore, how to provide a drug or therapy for locally advanced tumors that can replace radiotherapy has become a very important issue.

Hepatocellular carcinoma is a common liver malignancy. Clinical treatment methods for liver cancer include: surgery and non-surgical treatment; among them, non-surgical treatment can be divided into: hepatic artery embolization, alcohol injection, radiofrequency thermotherapy, and chemotherapy. For small liver malignant tumors, hepatocellular carcinoma can be killed by arterial embolization; and anticancer drugs or radiation substances can be added during arterial embolization to increase the lethal effect of hepatocellular carcinoma. However, clinical cases have shown that radiation therapy is not effective for liver cancer. In addition, extensive exposure to radiation can easily aggravate liver fibrosis and lead to other side effects. Therefore, how to improve the effect of arterial embolization on lethal hepatocellular carcinoma has become an important research goal.

Breast cancer treatments include surgical resection, radiation therapy, chemotherapy, and hormone therapy. Among them, chemotherapy is the use of anticancer drugs to destroy the production of cancer cells to achieve the purpose of killing cancer cells; usually, after breast cancer patients undergo surgery or radiation therapy, doctors may use this therapy as an adjuvant treatment to reduce the chance of cancer recurrence . Clinical cases have shown that the possible side effects of chemotherapy include: nausea, vomiting, loss of appetite, diarrhea, hair loss, oral ulcers, decreased hematopoietic function, and decreased blood cell count. Therefore, how to provide a therapeutic drug or therapy that can replace breast cancer anticancer drugs has become a very important issue.

Colorectal cancer often metastasizes to the liver, lungs, and bones through lymph glands or blood. Therefore, after surgical resection, colorectal cancer may still have microscopic metastases that cannot be discerned by the naked eye (surgeon). Therefore, after surgical treatment of colorectal cancer patients, doctors may use adjuvant chemotherapy to prevent local recurrence of tumors caused by these possible microscopic metastases. However, the most common acute side effects of chemotherapy for rectal cancer are diarrhea and inflammation of the perineal skin. In addition, the chronic side effects of chemotherapy for rectal cancer include small bowel obstruction, hemorrhage, perforation, and even necrosis.

From the above description, it can be easily known that for the treatment of lung cancer, liver cancer, breast cancer and colorectal cancer, surgery and chemotherapy (or radiation therapy) must be used in combination. However, chemotherapy drugs and radiopharmaceuticals (or radiation) will both affect Patients experience various side effects. In view of this, the present invention has been researched and invented to the utmost extent, and finally a pharmaceutical composition of the present invention for adjuvant treatment of cancer has been developed, wherein the pharmaceutical composition can replace chemical drugs or radioactive drugs for surgery of cancer patients subsequent adjuvant therapy.

Contents of the invention

The main purpose of the present invention is to provide a pharmaceutical composition for adjuvant treatment of cancer, which can not only achieve the effect of killing cancer cells, but also have the effects of clearing away heat and detoxification, enhancing immunity, and increasing appetite.

In order to achieve the above-mentioned main purpose of the present invention, the present invention provides a first embodiment of a pharmaceutical composition for adjuvant treatment of cancer, which is an extract of Antrodia camphorata; wherein, a specific dose is between 50 μg The extract between /mL and 250 μg/mL has the effect of treating a specific cancer.

In the first embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, wherein the specific cancer is selected from any one of the following groups: lung cancer, liver cancer, breast cancer, and colorectal cancer.

In the first embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, the extract can be any of the following: Antrodia antrodia water extract or Antrodia antrodia wine extract; and the extract can cause lung cancer The cell viability of cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 decreased by at least 50%.

And, in order to achieve the above-mentioned main purpose of the present invention, the present invention also provides a second embodiment of a pharmaceutical composition for adjuvant treatment of cancer, which is an extract of Ganoderma lucidum; wherein, a specific dosage The extract between 50 μg/mL and 250 μg/mL has the effect of treating a specific cancer.

In the second embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, wherein the specific cancer is selected from any one of the following groups: lung cancer, liver cancer, breast cancer, and colorectal cancer.

In the second embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, the extract can be any of the following: water extract of Ganoderma lucidum or wine extract of Ganoderma lucidum; and, the extract can cause lung cancer The cell viability of cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 decreased by at least 50%.

Moreover, in order to achieve the above-mentioned main purpose of the present invention, the present invention also provides a third embodiment of a pharmaceutical composition for adjuvant treatment of cancer, which is an Antrodia camphorata extract containing an Antrodia camphorata extract and a Ganoderma lucidum extract. Extract; wherein, the Gantrodia Antrodia extract with a specific dose between 50 μg/mL and 200 μg/mL has the effect of treating a specific cancer.

In the third embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, wherein the specific cancer is selected from any one of the following groups: lung cancer, liver cancer, breast cancer, and colorectal cancer.

In the third embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, wherein, the Ganoderma lucidum extract can be a Ganoderma lucidum water extract or a Ganoderma lucidum wine extract; and, the Antrodia camphorata extract can be a Water extract of Antrodia cintrodia or a wine extract of Antrodia cintrodia.

In the third embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, there is a specific mixing ratio between the Antrodia camphorata extract and the Ganoderma lucidum extract, and the specific mixing ratio is 1:1 to 10:1.

In the third embodiment of the aforementioned pharmaceutical composition for adjuvant treatment of cancer, wherein, the extract of Antrodia antrodia can cause lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT29 Cell viability drops by at least 50%.

The invention provides a pharmaceutical composition for adjuvant treatment of cancer. Unlike the prior art that uses anticancer drugs or radioactive substances to achieve the effect of killing cancer cells, the present invention uses Antrodia camphorata wine extract, Ganoderma lucidum wine extract, or Ganoderma lucidum wine extract as a novel pharmaceutical composition to achieve lethal Medical efficacy of lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29. In addition, compared with the existing anticancer drugs or radioactive substances that often have side effects such as nausea, vomiting, and loss of appetite, the wine extract of Antrodia camphorata, Ganoderma lucidum wine extract, or Ganoderma lucidum wine extract of the present invention can achieve In addition to the effect of killing cancer cells, it also has the effects of clearing heat and detoxification, enhancing immunity, and increasing appetite.

The present invention will be described in detail below in conjunction with the accompanying drawings and specific embodiments, but not as a limitation of the present invention.

Description of drawings

Figure 1 shows a graph of data showing cell viability versus extract concentration;

Fig. 2 shows the data graph of cell viability relative to the concentration of Antrodia camphorata wine extract;

Fig. 3 shows the data graph of cell viability relative to the concentration of Ganoderma lucidum wine extract;

Figure 4 shows the data curve of the cell survival rate versus the concentration of the wine extract of Antrodia camphorata.

detailed description

In order to more clearly describe a pharmaceutical composition for adjuvant treatment of cancer proposed by the present invention, preferred embodiments of the present invention will be described in detail below with reference to the drawings.

Antrodia cinnamomea is a very precious medicinal fungus, the main place of origin is Taiwan, China, also known as Taiwanofungus camphoratus. At present, the artificial cultivation methods of Antrodia camphorata are divided into: liquid fermentation method, solid cultivation method and basswood cultivation method. Research data shows that the fruiting body of Antrodia camphorata produced by basswood cultivation has good antioxidant and anti-cancer properties.

first embodiment

The first embodiment of a pharmaceutical composition for the auxiliary treatment of cancer proposed by the present invention is the extract of Antrodia camphorata (Antrodia camphorata), and the extract can be a water extract of Antrodia camphorata (water extract of Taiwanofungus camphoratus, TCWE ) or an Antrodia camphorata wine extract (ethanol extractof Taiwanofungus camphoratus, TCEE).

In the present invention, the wine extract of Antrodia Cinnamomea is used as an exemplary embodiment, and cell experiments are used to confirm that the wine extract of Antrodia Cinnamomea has the effect of assisting the treatment of cancer. Wherein, the Antrodia camphorata wine extract is obtained through an extraction process, and the extraction process includes the following process steps:

Step (S1): Prepare 10 grams of dry fruiting body powder of Antrodia camphorata and use 400 ml of ethanol as the extraction solution, then extract the dried fruiting body powder of Antrodia camphorata at 45-60° C. for 24 hours;

Step (S2): collecting a first extract from the aforementioned step (S1) and filtering it to obtain a first filtered extract and the dried Antrodia camphorata fruiting body powder after one extraction;

Step (S3): Using 400 ml of ethanol as the extraction solution, and then extracting the dried Antrodia camphorata fruiting body powder once extracted at 45-60° C. for 24 hours;

Step (S4): collecting a second extract from the aforementioned step (S3) and filtering it to obtain a second filtered extract;

Step (S5): mixing the first filtered extract and the second filtered extract to obtain a mixed extract, and concentrating the mixed extract to a thick state by blowing dry with nitrogen;

Step (S6): adding 1-2 mL of dimethyl sulfoxide (Dimethyl sulfoxide, DMSO) to the mixed extract to obtain a sample solution;

Step (S7): Filter the sample solution obtained in the above step (S6) with a membrane with 0.22-0.45um pores to remove microorganisms in the sample solution, and then take an appropriate dose (0-250 μg/mL) for cell experiments.

On the other hand, Ganoderma lucidum in a broad sense refers to the Ganodermaceae family, while Ganoderma lucidum in a narrow sense refers to a specific species that is widely cultivated. Ganoderma lucidum has been found to have good health effects, and can be divided into six types according to different colors: red, yellow, white, green, black, and purple. In the present invention, an extract of Ganoderma lucidum is used as the second embodiment of the pharmaceutical composition for adjuvant treatment of cancer. In the present invention, the extract of Ganoderma lucidum can be a water extract of Ganoderma lucidum (GLWE) or a wine extract of Ganoderma lucidum (GLEE), wherein the wine extract of Ganoderma lucidum can be It is produced through the above steps (S1) to (S6).

After obtaining the Antrodia Antrodia wine extract and the Ganoderma lucidum wine extract (ie, the first embodiment and the second embodiment), the present invention then completed the first experiment to confirm the normal use of the Antrodia camphorata wine extract and the Ganoderma lucidum wine extract Dosage range. In the first experiment, human epidermal cells HUVEC were treated with Antrodia camphorata wine extract and Ganoderma lucidum wine extract for 48 hours. See Figure 1 for a graph showing cell viability vs. extract concentration data. From Figure 1, we can find that high concentrations of Antrodia camphorata wine extract (285.2 μg/mL) and Ganoderma lucidum wine extract (377.4 μg/mL) have an inhibitory effect on human epidermal cells HUVEC.

Continuing, in order to verify the adjuvant cancer treatment effect of the pharmaceutical composition proposed by the present invention, the present invention completed the second experiment. In the second experiment, lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB231, and colorectal cancer cell HT 29 were treated with Antrodia camphorata wine extract at doses ranging from 0 μg/mL to 250 μg/mL. Please refer to Figure 2, which shows the data curve of cell viability versus the concentration of Antrodia camphorata wine extract. At the same time, the half maximal inhibitory concentration (half maximal inhibitory concentration) of the wine extract of Antrodia camphorata on the cell viability of lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 is summarized in the following table (1) middle. Thus, the experimental data of the second experiment confirmed that the Antrodia cinnamomea wine extract (i.e., the first embodiment) can indeed cause cell survival of lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 The cell viability is reduced by at least 50%; that is, the Antrodia camphorata wine extract has medicinal efficacy in treating lung cancer, liver cancer, breast cancer, and colorectal cancer.

Table I)

Further, the present invention completes the third experiment. In the third experiment, lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 were treated with ganoderma lucidum wine extract at doses ranging from 0 μg/mL to 250 μg/mL. Please refer to Figure 3, which shows the data curve of cell viability versus Ganoderma lucidum wine extract concentration. At the same time, the half-inhibitory concentration of Ganoderma lucidum wine extract on the cell viability of lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 is summarized in the following table (2). Thus, the experimental data of the third experiment confirmed that the Ganoderma lucidum wine extract (i.e., the third embodiment) can indeed cause cell survival of lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 The cell viability is reduced by at least 50%; that is, the Ganoderma lucidum wine extract has medicinal efficacy in treating lung cancer, liver cancer, breast cancer, and colorectal cancer.

Table II)

In addition to taking Antrodia camphorata wine extract and Ganoderma lucidum wine extract as the first embodiment and the second embodiment of the pharmaceutical composition of the present invention, the present invention further uses the Antrodia camphorata wine extract and the Ganoderma lucidum wine extract A wine extract of Antrodia camphorata is mixed in a specific mixing ratio, so as to serve as a third embodiment of the pharmaceutical composition of the present invention. Wherein, the specific mixing ratio is between 1:1 and 10:1.

In order to confirm the adjuvant cancer treatment effect of the third embodiment of the pharmaceutical composition, the present invention completed a fourth experiment. In the fourth experiment, a wine extract of Antrodia camphorata and a wine extract of Ganoderma lucidum were mixed to form a wine extract of Antrodia camphorata at a mixing ratio of 3.56:1; The wine extract of Antrodia camphorata treated lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 respectively. Please refer to Figure 4, which shows the data curve of cell viability versus the concentration of Gantrodia antrodia wine extract. At the same time, the half maximal inhibitory concentration (half maximal inhibitory concentration) of the wine extract of Antrodia camphorata on the cell viability of lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 is organized in the following table (three ) among. In this way, the experimental data of the fourth experiment confirmed that the wine extract of Antrodia camphorata (that is, the third embodiment) can indeed cause lung cancer cells A549, liver cancer cells Huh7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29 The cell viability is reduced by at least 50%; that is, the wine extract of Antrodia camphorata has medicinal efficacy in treating lung cancer, liver cancer, breast cancer, and colorectal cancer.

Table (3)

It is worth noting that biotech engineers who are familiar with pharmaceutical compositions can find out from Table (1), Table (2) and Table (3) that at the same dosage, the wine extract of Antrodia camphorata (the third embodiment) is The inhibitory effect on cancer cells is higher than that of Antrodia cintrodia wine extract (first embodiment), and the inhibitory effect on cancer cells of Antrodia camphorata wine extract (first embodiment) is higher than that of Ganoderma lucidum wine extract (second embodiment). To put it simply, the wine extract of Antrodia camphorata mixed with wine extract of Ganoderma lucidum can induce lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cells at a lower dose. The cell viability of HT 29 was reduced by at least 50%. It can be seen that the wine extract of Ganoderma lucidum can help enhance the cytotoxic effect of the wine extract of Antrodia camphorata.

Thus, the above has completely and clearly described the pharmaceutical composition for adjuvant treatment of cancer of the present invention, through the above, it can be known that the present invention has the following advantages:

(1) Unlike the prior art that uses anticancer drugs or radioactive substances to achieve the effect of killing cancer cells, the present invention uses Antrodia camphorata wine extract, Ganoderma lucidum wine extract, or Ganoderma lucidum wine extract as a novel pharmaceutical composition, To achieve the medical efficacy of killing lung cancer cells A549, liver cancer cells Huh7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29.

(2) In addition, compared with the existing anticancer drugs or radioactive substances that have side effects such as nausea, vomiting, and loss of appetite, the Antrodia camphorata wine extract, Ganoderma lucidum wine extract, or Gantrodia camphorata wine extract of the present invention In addition to the effect of killing cancer cells, it also has the effects of clearing away heat and detoxification, enhancing immunity, and increasing appetite.

Certainly, the present invention also can have other various embodiments, without departing from the spirit and essence of the present invention, those skilled in the art can make various corresponding changes and deformations according to the present invention, but these corresponding changes All changes and modifications should belong to the protection scope of the claims of the present invention.

Claims (13)

1. A pharmaceutical composition for adjuvant treatment of cancer, which is an extract of Antrodia cinnamomea; it is characterized in that the extract with a specific dose between 50 μg/mL and 250 μg/mL has the effect of treating a specific cancer effect. 2. The pharmaceutical composition for adjuvant treatment of cancer according to claim 1, characterized in that the extract can be any of the following: water extract of Antrodia cinnamomea or wine extract of Antrodia cinnamomea. 3. The pharmaceutical composition for adjuvant treatment of cancer according to claim 1, wherein the specific cancer is selected from any one of the following groups: lung cancer, liver cancer, breast cancer, and colorectal cancer. 4. The pharmaceutical composition for adjuvant treatment of cancer according to claim 3, characterized in that, the extract can cause lung cancer cell A549, liver cancer cell Huh7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29 Cell viability is reduced by at least 50%. 5. A pharmaceutical composition for adjuvant treatment of cancer, which is an extract of Ganoderma lucidum; it is characterized in that the extract with a specific dose between 50 μg/mL and 250 μg/mL has the effect of treating a specific cancer effect. 6. The pharmaceutical composition for adjuvant treatment of cancer according to claim 5, characterized in that the extract is any one of the following: water extract of Ganoderma lucidum or wine extract of Ganoderma lucidum. 7. The pharmaceutical composition for adjuvant treatment of cancer according to claim 5, wherein the specific cancer is selected from any one of the following groups: lung cancer, liver cancer, breast cancer, and colorectal cancer. 8. The pharmaceutical composition for adjuvant treatment of cancer according to claim 7, characterized in that the extract can cause lung cancer cells A549, liver cancer cells Huh7, breast cancer cells MDA-MB 231, colorectal cancer cells HT 29 cells Survival drops by at least 50%. 9. A pharmaceutical composition for adjuvant treatment of cancer, which is an Antrodia camphorata extract comprising an Antrodia cinnamomea extract and a Ganoderma lucidum extract; it is characterized in that a specific dose is between 50 μg/mL and 200 μg/mL Among them, the extract of Antrodia camphorata has the effect of treating a specific cancer. 10. The pharmaceutical composition for adjuvant treatment of cancer according to claim 9, characterized in that, the Ganoderma lucidum extract is a Ganoderma lucidum water extract or a Ganoderma lucidum wine extract; extract or antrodia camphorata wine extract. 11. The pharmaceutical composition for adjuvant treatment of cancer according to claim 9, characterized in that there is a specific mixing ratio between the Antrodia camphorata extract and the Ganoderma lucidum extract, and the specific mixing ratio is between 1:1 to 10:1. 12. The pharmaceutical composition for adjuvant treatment of cancer according to claim 9, wherein the specific cancer is selected from any one of the following groups: lung cancer, liver cancer, breast cancer, and colorectal cancer. 13. The pharmaceutical composition for adjuvant treatment of cancer according to claim 12, characterized in that the extract of Antrodia camphorata can cause lung cancer cells A549, liver cancer cells Huh7, breast cancer cells MDA-MB231, and colorectal cancer cells HT 29 had a drop in cell viability of at least 50%.